Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1934 • ACR Convergence 2023
Pooled Safety Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis
Stanley Cohen¹, Shaun Bender², Amy Shaberman³, Richard Vinisko³ and Dorothy McCabe³, ¹University of Texas Southwestern, Dallas, TX, ²Alnylam Pharmaceuticals, Cambridge, MA, ³Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT
Background/Purpose: The VOLTAIRE trials program compared the safety, efficacy, and immunogenicity of biosimilar BI 695501 with adalimumab reference product (RP) for indications including moderate-severe rheumatoid…
Abstract Number: 2105 • ACR Convergence 2023
Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases
Hiroaki Tanaka¹, Yukinori Okada², Shingo Nakayamada¹, Yusuke Miyazaki³, Kyuto Sonehara⁴, Shinichi Namba⁵, Suguru Honda⁶, Yuya Shirai⁷, Kenichi Yamamoto⁵, Katsunori Ikari⁸, Masayoshi Harigai⁹, KOSHIRO SONOMOTO¹⁰ and Yoshiya Tanaka¹, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²University of Tokyo / Osaka University / RIKEN, Tokyo, Japan, ³The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kiakyusyu Fukuoka, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Osaka University, Osaka, Japan, ⁶Tokyo Women's Medical University, Tokyo, Japan, ⁷Osaka University, Suita, Japan, ⁸Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁹Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹⁰University of Occupational and Environmental Health, Beppu, Japan
Background/Purpose: Autoimmune rheumatic diseases (AIRDs) are systemic but heterogeneous diseases characterized by orchestration of disrupted self-tolerance of immune systems. We face a challenge in characterizing…
Abstract Number: 2121 • ACR Convergence 2023
Clinical Significance of Negative Seroconversion of Anti-CCP and Anti-Mutated Citrullinated Vimentin Antibodies in Patients with Rheumatoid Arthritis
Takao Fujii, Katsunori Tanaka, Ryo Matsumiya, Kayoko Tabata and Shigeru Iwata, Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan
Background/Purpose: Anti-cyclic citrullinated peptide antibody (anti-CCP Ab) positivity is closely associated with bone destruction in rheumatoid arthritis (RA) patients, but the correlation between the Ab…
Abstract Number: 2137 • ACR Convergence 2023
Line of Therapy of Biologics and JAK Inhibitors in RA, PsA and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics
Jeffrey Curtis¹, Fenglong Xie¹, Yuji Su², Patrick Stewart³ and Amy S. Mudano¹, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham and Illumination Health, Birmingham, AL, ³Illumination Health, Birmingham, AL
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) have an increasing array of treatment options available, and new blood-based diagnostic…
Abstract Number: 2153 • ACR Convergence 2023
Effects of One-year Tofacitinib Therapy on Angiogenic Biomarkers in Rheumatoid Arthritis
György Kerekes¹, Monika Czókolyová¹, Attila Hamar¹, Anita Pusztai¹, Gábor Tajti¹, Mónika Katkó¹, Edit Végh¹, Zsófia Pethő¹, Nóra Bodnár¹, Ágnes Horváth¹, Boglárka Soós¹, Szilvia Szamosi¹, Zsolt Hascsi¹, Mariann Harangi¹, Katalin Hodosi¹, György Panyi¹, Tamas Seres², Gabriella Szücs¹ and Zoltán Szekanecz¹, ¹University of Debrecen, Faculty of Medicine, Debrecen, Hungary, ²University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Cardiovascular (CV) morbidity, mortality and perpetuated synovial angiogenesis have been associated with rheumatoid arthritis (RA). In our study we evaluated angiogenic factors in relation…
Abstract Number: 2170 • ACR Convergence 2023
Systemic Glucocorticoids Are Associated with a Time and Dose-dependent Risk of Major Adverse Cardiovascular Event in Patients with Rheumatoid Arthritis: A Population-based Study
Ho SO¹, Tommy LAM², Huan MENG³, Steven LAM³ and Lai-Shan Tam⁴, ¹The Chinese University of Hong Kong, Hong Kong, China, ²Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong, ³The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴The Chinese University of Hong Kong, New Territories, China
Background/Purpose: Rheumatoid arthritis (RA) and systemic glucocorticoid (GC) use are associated with increased risk of cardiovascular disease. The latest RA management recommendations from the American…
Abstract Number: 2450 • ACR Convergence 2023
Gene by Respiratory Disease Interactions Associated with Developing Rheumatoid Arthritis
Vanessa Kronzer¹, Keigo Hayashi², Cynthia Crowson¹, John Davis¹, Gregory McDermott², Jing Cui³, Elena Losina³, Pierre-Antoine Juge⁴, James Cerhan¹ and Jeffrey Sparks⁵, ¹Mayo Clinic, Rochester, MN, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cigarette smoking, textile dust, and occupational inhalants all strongly interact with the Human Leukocyte Antigen (HLA) shared epitope for risk of seropositive RA. Recently,…
Abstract Number: 2540 • ACR Convergence 2023
The Molecular Stratification of Rheumatoid Arthritis Using High-throughput Technologies Is Directly Associated with Disease Activity and Clinical Response
Ismael Sanchez-Pareja¹, Daniel Toro-Dominguez², Carlos Perez-Sanchez³, Laura Muñoz-Barrera¹, Tomás Cerdó¹, Rafaela Ortega Castro⁴, Jerusalem Calvo⁵, Marta Rojas⁶, Pilar Font Ugalde¹, Maria del Carmen Abalos-Aguilera⁷, Desiree Ruiz-Vilchez¹, Christian Merlo-Ruiz¹, Ivan Arias de la Rosa⁸, Mª Angeles Aguirre⁹, Eduardo Collantes Estévez¹⁰, Nuria Barbarroja¹¹, Marta Alarcon-Riquelme¹², Alejandro Escudero Contreras⁵ and Chary Lopez-Pedrera¹³, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²GENYO, Granada, Spain, ³IMIBIC, Córdoba, Spain, ⁴Hospital Reina Sofía, Cordoba, Spain, ⁵Reina Sofia University Hospital, Córdoba, Spain, ⁶Hospital Universitario Reina Sofía, Cordoba, Spain, ⁷Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁸IMIBIC/Reina Sofia Hospital/University of Cordoba. Rheumatology service. Cordoba. Spain, Cordoba, Spain, ⁹Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ¹⁰Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, ¹¹University of Cordoba, Córdoba, Spain, ¹²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹³IMIBIC - Reina Sofia Hospital, Córdoba, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a remarkably heterogeneous autoimmune disease whose clinical outcomes with disease-modifying antirheumatic drugs (DMARDs) remain unpredictable. The aim of this study…
Abstract Number: 0024 • ACR Convergence 2023
Detection of Synovial Signatures in Peripheral Blood of Patients with Rheumatoid Arthritis via a Novel Blood-Based DNA Capture Assay
Peter C. Taylor¹, Jenya Antonova², Jennifer Geis³, Katharine Dilger³, David Chernoff⁴, Diana Abdueva³, Nancy Shadick⁵ and Michael Weinblatt⁶, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Compass Strategy and Research, Inc., San Francisco, CA, ³Aqtual Inc., Hayward, CA, ⁴Chernoff Consulting, Sausalito, CA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Harvard Medical School, Waban, MA
Background/Purpose: In rheumatoid arthritis [RA], synovial biopsies were shown to guide therapy selection1. However, biopsies require special training for clinicians and are semi-invasive for patients.…
Abstract Number: 0086 • ACR Convergence 2023
Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
Stephen Parmley, Benjamin Szylyk, Richard Frank, Matthew Hsu, Polina Brodsky, Cailin Sibley, Paul Lizzul and Martin Dahl, AnaptysBio, San Diego, CA
Background/Purpose: Checkpoint antagonist therapeutics have transformed the field of oncology while advancing the understanding of adequate checkpoint activity in preventing autoimmunity. Checkpoint agonism represents a…
Abstract Number: 0220 • ACR Convergence 2023
Paxlovid (Nirmatrelvir Plus Ritonavir) in Patients with Underlying Rheumatological Diseases, in Preventing COVID-19 Related Hospitalization and Death
Faiza Javed, Tony Mangino and Paramarajan Piranavan, University of Kentucky College of Medicine, Lexington, KY
Background/Purpose: The benefits of antiviral therapy in the COVID-19 patients with underlying rheumatic disease with or without immunosuppression are not entirely clear. The goal of…
Abstract Number: 0385 • ACR Convergence 2023
Heterogeneity of the Joint Location Supports the Importance of Local Factors in Early RA Synovitis : Analysis of the ERA UCLouvain Brussels Cohort
Laura BRICMAN¹, clement triaille², Francesco Natalucci³, Emilie Sapart², Tatiana Sokolova⁴, Aleksandra AVRAMOVSKA¹, Thomas KIRCHGESNER⁵ and Patrick Durez², ¹Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ³UCLouvain University, Sermoneta, Italy, ⁴Université Catholique de Louvain, Brussels, Belgium, ⁵Rheumatology, Cliniques Universitaires Saint-Luc Département d'imagerie médicale – Université catholique de Louvain (UCLouvain), Brussels, Belgium
Background/Purpose: ERA is considered to be a systemic disorder, but the role of local factors in driving synovial inflammation is increasingly being recognized. These joint-specific…
Abstract Number: 0401 • ACR Convergence 2023
Resolution of Swollen Joint Count Is an Important Clinical Objective in Early Rheumatoid Arthritis : Analysis of the UCLouvain Brussels ERA Cohort and Comparison with the Remission Composite Index
Francesco Natalucci¹, clement triaille², Emilie Sapart², Laura BRICMAN³, Cécile VAN MULLEM², Charlotte Desmet², Stéphanie DIERCKX⁴, Marie DOYEN², Tatiana Sokolova⁵, Aleksandra AVRAMOVSKA³ and Patrick Durez², ¹UCLouvain University, Sermoneta, Italy, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ³Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁴CHU UCL Namur, Rheumatology, Mont-Godinne, Belgium, Mont Godinne, Belgium, ⁵Université Catholique de Louvain, Brussels, Belgium
Background/Purpose: Rheumatoid Arthritis is a chronic autoimmune disease characterized by persistent joint inflammation. According to international guidelines, the treatment target should aim to reach the…
Abstract Number: 0418 • ACR Convergence 2023
Synovial Fluid Cell Counts Associated with Joint Histopathology in Rheumatoid Arthritis
Edoardo Spolaore¹, Edward DiCarlo², Daniel Ramirez², Melanie Smith², Amit Lakhanpal², Bella Mehta³, Laura Donlin², Susan Goodman² and Dana Orange⁴, ¹HSS, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴The Rockefeller University, New York, NY
Background/Purpose: While analysis of synovial fluid white blood cell counts (WBCs) is performed in clinical practice for diagnosing septic arthritis and differentiating noninflammatory from inflammatory…
Abstract Number: 0435 • ACR Convergence 2023
Changes in Characteristics of Patients Initiating and Discontinuing Advanced Therapies for Rheumatoid Arthritis Following Release of Safety Data
Stephanie Song¹, Bryant England², Brian Sauer³, Michael George⁴, Beth Wallace⁵, Grant Cannon⁶, Ted R Mikuls⁷ and Joshua Baker⁴, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The ORAL Surveillance study highlighted risks of cardiac events, thromboembolism (VTE), and cancer associated with Janus kinase inhibitors (JAKi). The aim of this study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].